kymera
therapeutics
announces
third
quarter
financial
results
provides
business
update
well
positioned
advance
leading
pipeline
targeted
protein
degradation
medicines
recent
completion
upsized
initial
public
offering
strategic
collaboration
sanofi
reported
positive
interim
results
study
degrader
hs
patients
declared
irakimid
degrader
development
candidate
initiated
ind
enabling
activities
watertown
globe
newswire
kymera
therapeutics
nasdaq
kymr
biopharmaceutical
company
advancing
targeted
protein
degradation
deliver
novel
small
molecule
protein
degrader
therapeutics
today
reported
financial
results
third
quarter
ended
september
provided
business
update
kymera
made
significant
progress
since
company
founded
four
years
ago
commented
nello
mainolfi
president
ceo
kymera
investment
discovery
engine
delivering
unique
pipeline
potential
protein
degrader
medicines
allowing
us
address
diseases
completely
novel
way
rather
inhibiting
protein
function
leveraging
body
natural
recycling
machinery
degrade
proteins
made
great
strides
accelerate
path
becoming
fully
integrated
biotech
including
establishing
strategic
partnerships
sanofi
vertex
pharmaceuticals
extend
potential
impact
protein
degrader
therapies
even
patients
diseases
successful
ipo
completed
cash
runway
extends
well
positioned
advance
multiple
programs
oncology
diseases
first
program
expected
enter
clinic
first
half
quarterly
highlights
completed
initial
public
offering
ipo
august
kymera
closed
upsized
ipo
common
shares
including
exercise
full
underwriters
option
purchase
additional
common
shares
public
offering
price
per
share
concurrent
ipo
kymera
announced
sale
common
shares
public
offering
price
per
share
private
placement
vertex
pharmaceuticals
incorporated
existing
investor
total
gross
proceeds
kymera
deducting
underwriting
commissions
offering
expenses
approximately
million
august
kymera
closed
upsized
ipo
common
shares
including
exercise
full
underwriters
option
purchase
additional
common
shares
public
offering
price
per
share
concurrent
ipo
kymera
announced
sale
common
shares
public
offering
price
per
share
private
placement
vertex
pharmaceuticals
incorporated
existing
investor
total
gross
proceeds
kymera
deducting
underwriting
commissions
offering
expenses
approximately
million
announced
strategic
collaboration
sanofi
develop
commercialize
protein
degrader
therapies
terms
collaboration
signed
july
kymera
received
million
upfront
payment
earn
billion
potential
development
regulatory
sales
milestones
well
future
royalties
degraders
immunology
inflammation
indications
second
undisclosed
target
company
retains
ability
participate
equally
development
commercialization
programs
also
retains
full
rights
degraders
oncology
terms
collaboration
signed
july
kymera
received
million
upfront
payment
earn
billion
potential
development
regulatory
sales
milestones
well
future
royalties
degraders
immunology
inflammation
indications
second
undisclosed
target
company
retains
ability
participate
equally
development
commercialization
programs
also
retains
full
rights
degraders
oncology
presented
positive
interim
results
study
annual
symposium
hidradenitis
suppurativa
advances
shsa
virtual
conference
levels
shown
higher
active
hidradenitis
suppurativa
hs
lesions
compared
unaffected
skin
circulating
monocytes
additionally
ex
vivo
treatment
blood
hs
patients
lead
degrader
lowered
levels
across
peripheral
blood
mononuclear
cell
subsets
results
support
clinical
development
hs
diseases
link
poster
found
levels
shown
higher
active
hidradenitis
suppurativa
hs
lesions
compared
unaffected
skin
circulating
monocytes
additionally
ex
vivo
treatment
blood
hs
patients
lead
degrader
lowered
levels
across
peripheral
blood
mononuclear
cell
subsets
results
support
clinical
development
hs
diseases
link
poster
found
expanded
organization
addition
chief
scientific
officer
two
new
appointees
board
directors
recruiting
top
talent
remains
key
organizational
priority
meet
corporate
objectives
august
company
announced
appointment
richard
chesworth
chief
scientific
officer
chesworth
brings
proven
track
record
biopharmaceuticals
contributed
research
development
several
investigational
approved
drugs
september
company
announced
appointment
two
biopharmaceutical
veterans
jeff
albers
pamela
esposito
expand
board
directors
support
company
strategic
direction
mission
realize
promise
protein
degrader
therapies
patients
program
updates
milestones
kymera
discovering
developing
novel
small
molecule
therapeutics
selectively
degrade
disease
causing
proteins
harnessing
body
natural
protein
degradation
system
degrader
diseases
highly
active
selective
orally
bioavailable
degrader
developed
treatment
diseases
high
unmet
medical
need
diseases
include
hidradenitis
suppurativa
well
atopic
dermatitis
rheumatoid
arthritis
kymera
expects
file
investigational
new
drug
ind
application
cleared
begin
phase
clinical
trial
first
half
highly
active
selective
orally
bioavailable
degrader
developed
treatment
diseases
high
unmet
medical
need
diseases
include
hidradenitis
suppurativa
well
atopic
dermatitis
rheumatoid
arthritis
kymera
expects
file
investigational
new
drug
ind
application
cleared
begin
phase
clinical
trial
first
half
irakimid
degrader
lymphoma
irakimids
degraders
unique
profile
combines
activity
degradation
imids
single
agent
address
tlr
type
ifn
pathways
synergistically
generate
broad
activity
b
cell
lymphomas
third
quarter
kymera
declared
development
candidate
initiated
ind
enabling
activities
kymera
expects
file
ind
cleared
begin
phase
clinical
trial
second
half
strong
antitumor
activity
allows
intermittent
dosing
consistent
initial
plans
intravenous
formulation
due
current
clinical
entry
point
diffuse
large
b
cell
lymphoma
dlbcl
equally
efficacious
dosed
orally
development
oral
formulation
also
evaluated
characterization
presented
american
society
hematology
annual
meeting
december
link
press
release
announcing
abstracts
found
irakimids
degraders
unique
profile
combines
activity
degradation
imids
single
agent
address
tlr
type
ifn
pathways
synergistically
generate
broad
activity
b
cell
lymphomas
third
quarter
kymera
declared
development
candidate
initiated
ind
enabling
activities
kymera
expects
file
ind
cleared
begin
phase
clinical
trial
second
half
strong
antitumor
activity
allows
intermittent
dosing
consistent
initial
plans
intravenous
formulation
due
current
clinical
entry
point
diffuse
large
b
cell
lymphoma
dlbcl
equally
efficacious
dosed
orally
development
oral
formulation
also
evaluated
characterization
presented
american
society
hematology
annual
meeting
december
link
press
release
announcing
abstracts
found
degrader
oncologic
diseases
program
developed
treatment
hematological
malignancies
solid
tumors
well
autoimmune
diseases
fibrosis
transcription
factor
activated
variety
different
cytokine
growth
factor
receptors
via
janus
kinases
jaks
well
oncogenic
fusion
proteins
mutations
kymera
continues
expect
file
ind
cleared
begin
phase
clinical
trial
second
half
lead
degrader
data
presented
american
society
hematology
annual
meeting
december
link
press
release
announcing
abstracts
found
third
quarter
financial
results
collaboration
revenues
total
revenues
quarter
ended
september
million
compared
million
period
collaboration
revenue
includes
revenue
sanofi
vertex
collaborations
vertex
research
development
expenses
research
development
expenses
million
quarter
ended
september
compared
million
period
increase
primarily
due
higher
direct
expenses
related
studies
irak
programs
lead
optimization
activities
programs
investment
platform
exploratory
programs
vertex
collaboration
well
increase
occupancy
related
costs
due
continued
growth
research
development
organization
general
administrative
expenses
general
administrative
expenses
million
quarter
ended
september
compared
million
period
increase
primarily
due
increases
legal
professional
service
fees
support
growth
increase
personnel
facility
expenses
stemming
increase
headcount
support
operations
public
company
net
loss
net
loss
quarter
ended
september
million
per
share
compared
net
loss
million
per
share
period
cash
cash
equivalents
september
kymera
approximately
million
cash
cash
equivalents
investments
kymera
expects
current
cash
cash
equivalents
investments
september
excluding
future
potential
milestones
collaborations
enable
company
fund
operational
plans
kymera
therapeutics
kymera
therapeutics
biopharmaceutical
company
focused
transformative
new
approach
address
previously
intractable
disease
targets
kymera
advancing
field
targeted
protein
degradation
accessing
body
innate
protein
recycling
machinery
degrade
dysregulated
proteins
kymera
targeted
protein
degradation
platform
harnesses
body
natural
protein
recycling
machinery
degrade
proteins
focus
nodes
validated
pathways
currently
inaccessible
conventional
therapeutics
kymera
accelerating
drug
discovery
unmatched
ability
target
degrade
intractable
proteins
advance
new
treatment
options
patients
kymera
initial
programs
target
irakimid
within
tlr
jak
stat
pathways
providing
opportunity
treat
broad
range
diseases
hematologic
malignancies
solid
tumors
information
visit
kymera
therapeutics
proprietary
protein
degradation
platform
created
team
experienced
drug
hunters
improve
effectiveness
targeted
protein
degradation
generate
pipeline
novel
therapeutics
previously
undruggable
diseases
platform
consists
informatics
driven
target
identification
novel
ligases
proprietary
ternary
complex
predictive
modeling
capabilities
degradation
tools
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
implied
express
statements
regarding
strategy
expectations
regarding
cash
runway
strategy
business
plans
focus
plans
timelines
clinical
development
kymera
therapeutics
product
candidates
therapeutic
potential
clinical
benefits
thereof
growth
company
expectations
regarding
future
interactions
food
drug
administration
fda
including
timelines
filing
inds
uses
capital
words
may
might
could
would
expect
plan
anticipate
intend
believe
expect
estimate
seek
predict
future
project
potential
continue
target
similar
words
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
associated
impact
countries
regions
operations
business
well
timing
anticipated
results
current
preclinical
studies
future
clinical
trials
strategy
future
operations
delay
current
preclinical
studies
future
clinical
trials
development
kymera
therapeutics
drug
candidates
risk
results
current
preclinical
studies
may
predictive
future
results
connection
future
clinical
trials
kymera
therapeutics
ability
successfully
demonstrate
safety
efficacy
drug
candidates
timing
outcome
company
planned
interactions
regulatory
authorities
obtaining
maintaining
protecting
intellectual
property
risks
uncertainties
described
greater
detail
section
entitled
risk
factors
included
quarterly
report
form
quarter
ended
september
well
discussions
potential
risks
uncertainties
important
factors
kymera
therapeutics
subsequent
filings
securities
exchange
commission
addition
statements
represent
kymera
therapeutics
views
today
relied
upon
representing
views
subsequent
date
kymera
therapeutics
explicitly
disclaims
obligation
update
statements
representations
warranties
expressed
implied
made
accuracy
statements
investors
investors
bruce
jacobs
chief
financial
officer
christopher
brinzey
westwicke
icr
company
kymera
therapeutics
media
media
lissette
steele
verge
scientific
communications
kymera
therapeutics
lsteele
kymera
therapeutics
condensed
consolidated
statements
operations
comprehensive
loss
three
nine
months
ended
september
thousands
except
share
per
share
amounts
unaudited
three
months
ended
september
nine
months
ended
september
collaboration
related
parties
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
operations
income
expense
interest
income
interest
expense
total
income
net
loss
deemed
dividend
exchange
convertible
preferred
stock
net
loss
attributable
common
stockholders
net
loss
per
share
attributable
common
stockholders
basic
diluted
weighted
average
common
stocks
outstanding
basic
diluted
kymera
therapeutics
condensed
consolidated
balance
sheets
thousands
except
share
per
share
amounts
unaudited
september
december
assets
cash
cash
equivalents
marketable
securities
property
equipment
net
assets
total
assets
liabilities
stockholders
equity
deficit
deferred
revenue
liabilities
total
liabilities
preferred
stock
total
stockholders
equity
deficit
total
liabilities
preferred
stock
stockholders
equity
deficit
